对阿尔茨海默病生物标志物,途径和子组识别的等离子体蛋白质组分析
Carmen Peña-Bautista1, Lourdes Álvarez-Sánchez1, Ángel Balaguer2
1Alzheimer's Disease Research Group, Instituto de Investigación Sanitaria La Fe, Valencia 46026, Spain.
Journal of proteome research
|July 10, 2025
概括
这项研究确定了10种血蛋白作为早期阿尔茨海默病 (AD) 检测的潜在生物标志物. 这些发现有助于理解AD.
科学领域:
- 蛋白质组学是指蛋白质组学.
- 神经科学是一个神经科学.
- 生物标志物发现发现
背景情况:
- 血蛋白质组分析有助于识别阿尔茨海默氏症 (AD) 等复杂疾病的生物标志物.
- 早期发现和了解AD亚型对于有效管理至关重要.
研究的目的:
- 为了确定潜在的血生物标志物用于早期检测由于AD的轻度认知障碍 (MCI-AD).
- 阐明受影响的生物途径,并确定不同的MCI-AD子组.
主要方法:
- 基于MCI-AD和主观认知障碍 (SCI) 患者的血样本上的非定向质谱蛋白质组学.
- 使用了差异分析 (PLS回归,火山图) 和集群分析.
- 用STRING数据库进行路径分析.
主要成果:
- 检测到了1094种蛋白质,其中71种蛋白质显示MCI-AD和SCI组之间的显著差异.
- 通过PLS和火山情景分析分别确定了45个和22个变量.
- 改变的途径包括免疫系统,细胞粘附和蛋白质分解;确定了两个MCI-AD亚组.
结论:
- 十种蛋白质被确定为早期AD检测的潜在血生物标志物.
- 这项研究突出了受影响的生物学途径,促进了对AD病理学方面的理解.
- 这些发现有助于早期AD诊断和个性化治疗策略.
相关概念视频
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265